Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
5(83.3%)
Phase 3
1(16.7%)
6Total
Phase 2(5)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01264328Phase 2Completed

Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer

Role: collaborator

NCT01285778Phase 2Completed

Vectibix for the Treatment of Anal Cancer

Role: collaborator

NCT01379807Phase 2Unknown

Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Role: collaborator

NCT01577784Phase 2Unknown

Pazopanib in Second-line Therapy in Renal Cell Carcinoma

Role: collaborator

NCT01065857Phase 3Completed

Safety and Efficacy Study of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.

Role: collaborator

NCT00251381Phase 2Unknown

Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.

Role: lead

All 6 trials loaded